collection
MENU ▼
Read by QxMD icon Read
search

Neuroradiology CNS tumours

shared collection
101 papers 25 to 100 followers Neuroradiology articles related to central nervous system tumours.
By Sebastian Bravo-Grau Neuroradiology Fellow - Radiologist
https://www.readbyqxmd.com/read/28833756/multinodular-and-vacuolating-neuronal-tumors-in-epilepsy-dysplasia-or-neoplasia
#1
Maria Thom, Joan Liu, Anika Bongaarts, Roy J Reinten, Beatrice Paradiso, Hans Rolf Jäger, Cheryl Reeves, Alyma Somani, Shu An, Derek Marsdon, Andrew McEvoy, Anna Miserocchi, Lewis Thorne, Fay Newman, Sorin Bucur, Mrinalini Honavar, Tom Jacques, Eleonora Aronica
Multinodular and vacuolating neuronal tumor (MVNT) is a new pattern of neuronal tumour included in the recently revised WHO 2016 classification of tumors of the CNS. There are 15 reports in the literature to date. They are typically associated with late onset epilepsy and a neoplastic vs. malformative biology has been questioned. We present a series of ten cases and compare their pathological and genetic features to better characterized epilepsy-associated malformations including focal cortical dysplasia type II (FCDII) and low-grade epilepsy-associated tumors (LEAT)...
March 2018: Brain Pathology
https://www.readbyqxmd.com/read/28944505/taxonomy-of-cns-tumours-a-series-of-three-short-reviews-on-the-who-2016-classification-and-beyond
#2
EDITORIAL
P Wesseling, T S Jacques
No abstract text is available yet for this article.
February 2018: Neuropathology and Applied Neurobiology
https://www.readbyqxmd.com/read/28949028/cns-embryonal-tumours-who-2016-and-beyond
#3
REVIEW
J C Pickles, C Hawkins, T Pietsch, T S Jacques
Embryonal tumours of the central nervous system (CNS) present a significant clinical challenge. Many of these neoplasms affect young children, have a very high mortality and therapeutic strategies are often aggressive with poor long-term outcomes. There is a great need to accurately diagnose embryonal tumours, predict their outcome and adapt therapy to the individual patient's risk. For the first time in 2016, the WHO classification took into account molecular characteristics for the diagnosis of CNS tumours...
February 2018: Neuropathology and Applied Neurobiology
https://www.readbyqxmd.com/read/29304360/clinical-trial-design-for-local-therapies-for-brain-metastases-a-guideline-by-the-response-assessment-in-neuro-oncology-brain-metastases-working-group
#4
REVIEW
Brian M Alexander, Paul D Brown, Manmeet S Ahluwalia, Hidefumi Aoyama, Brigitta G Baumert, Susan M Chang, Laurie E Gaspar, Steven N Kalkanis, David R Macdonald, Minesh P Mehta, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Jeffrey S Wefel, Eudocia Q Lee, Patrick Y Wen
The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints...
January 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29261148/advances-in-brain-tumor-surgery-for-glioblastoma-in-adults
#5
REVIEW
Montserrat Lara-Velazquez, Rawan Al-Kharboosh, Stephanie Jeanneret, Carla Vazquez-Ramos, Deependra Mahato, Daryoush Tavanaiepour, Gazanfar Rahmathulla, Alfredo Quinones-Hinojosa
Glioblastoma (GBM) is the most common primary intracranial neoplasia, and is characterized by its extremely poor prognosis. Despite maximum surgery, chemotherapy, and radiation, the histological heterogeneity of GBM makes total eradication impossible, due to residual cancer cells invading the parenchyma, which is not otherwise seen in radiographic images. Even with gross total resection, the heterogeneity and the dormant nature of brain tumor initiating cells allow for therapeutic evasion, contributing to its recurrence and malignant progression, and severely impacting survival...
December 20, 2017: Brain Sciences
https://www.readbyqxmd.com/read/28982791/radiomics-in-brain-tumor-image-assessment-quantitative-feature-descriptors-and-machine-learning-approaches
#6
REVIEW
M Zhou, J Scott, B Chaudhury, L Hall, D Goldgof, K W Yeom, M Iv, Y Ou, J Kalpathy-Cramer, S Napel, R Gillies, O Gevaert, R Gatenby
Radiomics describes a broad set of computational methods that extract quantitative features from radiographic images. The resulting features can be used to inform imaging diagnosis, prognosis, and therapy response in oncology. However, major challenges remain for methodologic developments to optimize feature extraction and provide rapid information flow in clinical settings. Equally important, to be clinically useful, predictive radiomic properties must be clearly linked to meaningful biologic characteristics and qualitative imaging properties familiar to radiologists...
February 2018: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29074637/mr-elastography-analysis-of-glioma-stiffness-and-idh1-mutation-status
#7
K M Pepin, K P McGee, A Arani, D S Lake, K J Glaser, A Manduca, I F Parney, R L Ehman, J Huston
BACKGROUND AND PURPOSE: Our aim was to noninvasively evaluate gliomas with MR elastography to characterize the relationship of tumor stiffness with tumor grade and mutations in the isocitrate dehydrogenase 1 (IDH1) gene. MATERIALS AND METHODS: Tumor stiffness properties were prospectively quantified in 18 patients (mean age, 42 years; 6 women) with histologically proved gliomas using MR elastography from 2014 to 2016. Images were acquired on a 3T MR imaging unit with a vibration frequency of 60 Hz...
October 26, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29122763/prediction-of-idh1-mutation-and-1p-19q-codeletion-status-using-preoperative-mr-imaging-phenotypes-in-lower-grade-gliomas
#8
Y W Park, K Han, S S Ahn, S Bae, Y S Choi, J H Chang, S H Kim, S-G Kang, S-K Lee
BACKGROUND AND PURPOSE: WHO grade II gliomas are divided into three classes: isocitrate dehydrogenase (IDH) -wildtype, IDH -mutant and no 1p/19q codeletion, and IDH -mutant and 1p/19q-codeleted. Different molecular subtypes have been reported to have prognostic differences and different chemosensitivity. Our aim was to evaluate the predictive value of imaging phenotypes assessed with the Visually AcceSAble Rembrandt Images lexicon for molecular classification of lower grade gliomas. MATERIALS AND METHODS: MR imaging scans of 175 patients with lower grade gliomas with known IDH1 mutation and 1p/19q-codeletion status were included (78 grade II and 97 grade III) in the discovery set...
January 2018: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28922780/use-of-alternative-medicine-for-cancer-and-its-impact-on-survival
#9
Skyler B Johnson, Henry S Park, Cary P Gross, James B Yu
There is limited available information on patterns of utilization and efficacy of alternative medicine (AM) for patients with cancer. We identified 281 patients with nonmetastatic breast, prostate, lung, or colorectal cancer who chose AM, administered as sole anticancer treatment among patients who did not receive conventional cancer treatment (CCT), defined as chemotherapy, radiotherapy, surgery, and/or hormone therapy. Independent covariates on multivariable logistic regression associated with increased likelihood of AM use included breast or lung cancer, higher socioeconomic status, Intermountain West or Pacific location, stage II or III disease, and low comorbidity score...
January 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29028423/2016-updates-to-the-who-brain-tumor-classification-system-what-the-radiologist-needs-to-know
#10
REVIEW
Derek R Johnson, Julie B Guerin, Caterina Giannini, Jonathan M Morris, Lawrence J Eckel, Timothy J Kaufmann
Radiologists play a key role in brain tumor diagnosis and management and must stay abreast of developments in the field to advance patient care and communicate with other health care providers. In 2016, the World Health Organization (WHO) released an update to its brain tumor classification system that included numerous significant changes. Several previously recognized brain tumor diagnoses, such as oligoastrocytoma, primitive neuroectodermal tumor, and gliomatosis cerebri, were redefined or eliminated altogether...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28885122/clinicopathological-variables-of-sporadic-schwannomas-of-peripheral-nerve-in-291-patients-and-expression-of-biologically-relevant-markers
#11
Eric D Young, Davis Ingram, William Metcalf-Doetsch, Dilshad Khan, Ghadah Al Sannaa, Francois Le Loarer, Alexander J F Lazar, John Slopis, Keila E Torres, Dina Lev, Raphael E Pollock, Ian E McCutcheon
OBJECTIVE While sporadic peripheral schwannomas (SPSs) are generally well treated with surgery, their biology is not well understood. Consequently, treatment options are limited. The aim of this study was to provide a comprehensive description of SPS. The authors describe clinicopathological features and treatment outcomes of patients harboring these tumors, and they assess expression of biomarkers using a clinically annotated tissue microarray. Together, these data give new insight into the biology and management of SPS...
September 8, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28642265/the-initial-area-under-the-curve-derived-from-dynamic-contrast-enhanced-mri-improves-prognosis-prediction-in-glioblastoma-with-unmethylated-mgmt-promoter
#12
Y S Choi, S S Ahn, H-J Lee, J H Chang, S-G Kang, E H Kim, S H Kim, S-K Lee
BACKGROUND AND PURPOSE: Although perfusion and permeability MR parameters have known to have prognostic value, they have reproducibility issues. Our aim was to evaluate whether the initial area under the time-to-signal intensity curve (IAUC) derived from dynamic contrast-enhanced MR imaging can improve prognosis prediction in patients with glioblastoma with known MGMT status. MATERIALS AND METHODS: We retrospectively examined 88 patients with glioblastoma who underwent preoperative dynamic contrast-enhanced MR imaging...
August 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28663266/relationship-between-glioblastoma-heterogeneity-and-survival-time-an-mr-imaging-texture-analysis
#13
Y Liu, X Xu, L Yin, X Zhang, L Li, H Lu
BACKGROUND AND PURPOSE: The heterogeneity of glioblastoma contributes to the poor and variant prognosis. The aim of this retrospective study was to assess the glioblastoma heterogeneity with MR imaging textures and to evaluate its impact on survival time. MATERIALS AND METHODS: A total of 133 patients with primary glioblastoma who underwent postcontrast T1-weighted imaging (acquired before treatment) and whose data were filed with the survival times were selected from the Cancer Genome Atlas...
September 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28642179/analysis-of-outcomes-of-multidisciplinary-management-of-gliosarcoma-a-single-center-study-2000-2013
#14
Abhinav Jain, Jason Correia, Patrick Schweder, Adele McMahon, Joseph Merola, Robert Aspoas
BACKGROUND: Gliosarcoma is a rare tumor of the central nervous system with a reported incidence of ∼2%-8% of all gliomas. We reviewed the outcomes of patients treated at our institution over a 14-year period from 2000 to 2013 to characterize overall survival (OS) and progression-free survival as well as to elucidate the additive effect of chemoradiotherapy. METHODS: From January 1, 2000 to December 31, 2013, we retrospectively reviewed the clinical notes of all patients treated at our institution with a histopathologic diagnosis of gliosarcoma...
October 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28598278/atypical-pituitary-adenoma-a-clinicopathologic-case-series
#15
Martin J Rutkowski, Ryan M Alward, Rebecca Chen, Jeffrey Wagner, Arman Jahangiri, Derek G Southwell, Sandeep Kunwar, Lewis Blevins, Han Lee, Manish K Aghi
OBJECTIVE In 2004, the WHO classified atypical pituitary adenoma as a distinct adenoma subtype. However, the clinical significance of this distinction remains undetermined. The authors sought to define patient characteristics, tumor features, and treatment outcomes associated with atypical pituitary adenoma. METHODS The authors reviewed records of patients who underwent resection of pituitary adenoma at the University of California, San Francisco, between 2007 and 2014. Per institutional protocol, adenomas exhibiting mitotic activity underwent evaluation for all 3 markers of atypicality (mitotic index, extensive p53 staining, and MIB-1 index ≥ 3%)...
June 9, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28591823/the-survival-advantage-of-supratotal-resection-of-glioblastoma-using-selective-cortical-mapping-and-the-subpial-technique
#16
(no author information available yet)
No abstract text is available yet for this article.
August 1, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28540482/linear-sign-in-cystic-brain-lesions-%C3%A2-5-mm-a-suggestive-feature-of-perivascular-space
#17
Jinkyeong Sung, Jinhee Jang, Hyun Seok Choi, So-Lyung Jung, Kook-Jin Ahn, Bum-Soo Kim
OBJECTIVE: To determine the prevalence of a linear sign within enlarged perivascular space (EPVS) and chronic lacunar infarction (CLI) ≥ 5 mm on T2-weighted imaging (T2WI) and time-of-flight (TOF) magnetic resonance angiography (MRA), and to evaluate the diagnostic value of the linear signs for EPVS over CLI. METHODS: This study included 101 patients with cystic lesions ≥ 5 mm on brain MRI including TOF MRA. After classification of cystic lesions into EPVS or CLI, two readers assessed linear signs on T2WI and TOF MRA...
November 2017: European Radiology
https://www.readbyqxmd.com/read/28483413/european-association-for-neuro-oncology-eano-guideline-on-the-diagnosis-and-treatment-of-adult-astrocytic-and-oligodendroglial-gliomas
#18
REVIEW
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot, Martin Bendszus, Jaap C Reijneveld, Frederick Dhermain, Pim French, Christine Marosi, Colin Watts, Ingela Oberg, Geoffrey Pilkington, Brigitta G Baumert, Martin J B Taphoorn, Monika Hegi, Manfred Westphal, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick
The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice...
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28548599/an-extent-of-resection-threshold-for-seizure-freedom-in-patients-with-low-grade-gliomas
#19
David S Xu, Al-Wala Awad, Chad Mehalechko, Jeffrey R Wilson, Lynn S Ashby, Stephen W Coons, Nader Sanai
OBJECTIVE Seizures are the most common presenting symptom of newly diagnosed WHO Grade II gliomas (low-grade glioma [LGG]) and significantly impair quality of life. Although gross-total resection of LGG is associated with better seizure control, it remains unclear whether an extent of resection (EOR) "threshold" exists for long-term seizure control. Specifically, what proportion of FLAIR-positive tissue in patients with newly diagnosed LGG must be removed to achieve Engel Class I seizure freedom? To clarify the EOR threshold for long-term seizure control, the authors analyzed data from a consecutive series of patients with newly diagnosed LGG who presented with seizures and subsequently underwent microsurgical resection...
May 26, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28493907/edema-is-not-a-reliable-diagnostic-sign-to-exclude-small-brain-metastases
#20
Tanja Schneider, Jan Felix Kuhne, Paul Bittrich, Julian Schroeder, Tim Magnus, Malte Mohme, Malte Grosser, Gerhard Schoen, Jens Fiehler, Susanne Siemonsen
No prior systematic study on the extent of vasogenic edema (VE) in patients with brain metastases (BM) exists. Here, we aim to determine 1) the general volumetric relationship between BM and VE, 2) a threshold diameter above which a BM shows VE, and 3) the influence of the primary tumor and location of the BM in order to improve diagnostic processes and understanding of edema formation. This single center, retrospective study includes 173 untreated patients with histologically proven BM. Semi-manual segmentation of 1416 BM on contrast-enhanced T1-weighted images and of 865 VE on fluid-attenuated inversion recovery/T2-weighted images was conducted...
2017: PloS One
label_collection
label_collection
7076
1
2
2017-05-15 08:49:48
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"